Toronto, Ontario–(Newsfile Corp. – December 3, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming virtual December investor conferences.
H.C. Wainwright 2nd Annual Psychedelics Conference
Presentation: On Demand Beginning Monday, December 6th at 7:00 a.m. ET
Registration: Click here
Stifel GMP 2nd Annual The Future of Healthcare Conference
Presentation: Wednesday, December 8th at 2:00 p.m. ET
Registration: Click here
For more information about each conference, or to schedule a one-on-one meeting with Awakn’s management team, please contact your Stifel representative, H.C. Wainwright representative or KCSA Strategic Communications at [email protected].
About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver these evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally.
www.awaknlifesciences.com | Twitter | LinkedIn | Facebook
Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]
Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
[email protected]
Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106319
Powered by WPeMatico
